ANGIOPREDICT - an FP7-funded project enabling personalised medicine for patients with metastatic colorectal cancer.
Ontology highlight
ABSTRACT: In ANGIOPREDICT, academic cancer biologists and industry-based biotechnology researchers will work together with clinicians to identify biomarkers to predict whether individual metastatic colorectal cancer patients will respond positively to Avastin® combination therapy. Diagnostic tests using these biomarkers will also be developed to provide clinicians with the means to predict patient treatment responses in the future.
PROVIDER: EGAS00001005423 | EGA |
REPOSITORIES: EGA
ACCESS DATA